Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Shares Issued: 2020-2024

Historic Shares Issued for 4D Molecular Therapeutics (FDMT) over the last 2 years, with Dec 2024 value amounting to -$300.8 million.

  • 4D Molecular Therapeutics' Shares Issued was N/A to -$300.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $15.3 million, marking a year-over-year change of. This contributed to the annual value of $15.3 million for FY2024, which is 88.16% down from last year.
  • According to the latest figures from Q4 2024, 4D Molecular Therapeutics' Shares Issued is -$300.8 million, which was down 30,085,000.00% from $1,000 recorded in Q3 2024.
  • 4D Molecular Therapeutics' Shares Issued's 5-year high stood at $281.2 million during Q2 2024, with a 5-year trough of -$300.8 million in Q4 2024.
  • Its 3-year average for Shares Issued is $16.1 million, with a median of $875,000 in 2022.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Shares Issued plummeted by 44.16% in 2021 and then soared by 14,763.31% in 2023.
  • 4D Molecular Therapeutics' Shares Issued (Quarterly) stood at $204.7 million in 2020, then plummeted by 44.16% to $114.3 million in 2021, then surged by 783.84% to -$875,000 in 2022, then surged by 14,763.31% to -$512,000 in 2023, then skyrocketed by 100.20% to -$300.8 million in 2024.
  • Its last three reported values are -$300.8 million in Q4 2024, $1,000 for Q3 2024, and $281.2 million during Q2 2024.